Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Redifferentiating agents in non-radioiodine avid cancer.
Seregni E, Vellani C, Castellani MR, Maccauro M, Pallotti F, Scaramellini G, Guzzo M, Greco A. Seregni E, et al. Q J Nucl Med Mol Imaging. 2009 Oct;53(5):513-9. Q J Nucl Med Mol Imaging. 2009. PMID: 19910904 Free article. Review.
Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.
Borrello MG, Aiello A, Peissel B, Rizzetti MG, Mondellini P, Degl'Innocenti D, Catalano V, Gobbo M, Collini P, Bongarzone I, Pierotti MA, Greco A, Seregni E. Borrello MG, et al. Among authors: seregni e. Endocr Relat Cancer. 2011 Jul 25;18(4):519-27. doi: 10.1530/ERC-10-0306. Print 2011 Aug. Endocr Relat Cancer. 2011. PMID: 21690267
Evidence of oncogene-induced senescence in thyroid carcinogenesis.
Vizioli MG, Possik PA, Tarantino E, Meissl K, Borrello MG, Miranda C, Anania MC, Pagliardini S, Seregni E, Pierotti MA, Pilotti S, Peeper DS, Greco A. Vizioli MG, et al. Among authors: seregni e. Endocr Relat Cancer. 2011 Dec 1;18(6):743-57. doi: 10.1530/ERC-11-0240. Print 2011 Dec. Endocr Relat Cancer. 2011. PMID: 21937739
DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D, Romeo P, Tarantino E, Sensi M, Cassinelli G, Catalano V, Lanzi C, Perrone F, Pilotti S, Seregni E, Pierotti MA, Greco A, Borrello MG. Degl'Innocenti D, et al. Among authors: seregni e. Endocr Relat Cancer. 2013 Jan 21;20(1):23-37. doi: 10.1530/ERC-12-0078. Print 2013 Feb. Endocr Relat Cancer. 2013. PMID: 23132790
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.
Pusceddu S, Corti F, Prinzi N, Nichetti F, Ljevar S, Busico A, Cascella T, Leporati R, Oldani S, Pircher CC, Coppa J, Resi V, Milione M, Maccauro M, Miceli R, Tamborini E, Perrone F, Spreafico C, Niger M, Morano F, Pietrantonio F, Seregni E, Mariani L, Mazzaferro V, Di Liberti G, Fucà G, de Braud F, Vernieri C. Pusceddu S, et al. Among authors: seregni e. J Hematol Oncol. 2023 Dec 14;16(1):119. doi: 10.1186/s13045-023-01510-9. J Hematol Oncol. 2023. PMID: 38098114 Free PMC article. Clinical Trial.
211 results